# PEG6000

**Cat. No.:** HY-Y0873I

**CAS No.:** 25322-68-3


**Molecular Weight:** 6000.00

**Target:** Environmental Pollutants; Biochemical Assay Reagents

**Pathway:** Others

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

$H_2O$ : 100 mg/mL (16.67 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 0.1667 mL | 0.8333 mL | 1.6667 mL |
| | 5 mM | 0.0333 mL | 0.1667 mL | 0.3333 mL |
| | 10 mM | 0.0167 mL | 0.0833 mL | 0.1667 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

PEG6000 can be used as an excipient, such as Ointment base, lubricant, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs[1].

**In Vitro**

The FDA has approved polyethylene glycol (PEG) for use as a vehicle or base in foods, cosmetics and pharmaceuticals, including injectable, topical, rectal and nasal formulations. PEG shows little toxicity, and is eliminated from the body intact by either the kidneys (for PEGs < 30 kDa) or in the faeces (for PEGs > 20 kDa). PEG lacks immunogenicity, and antibodies to PEG are generated in rabbits only if PEG is combined with highly immunogenic proteins[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cell Metab. 2025 Dec 22.
- Phytomedicine. 2025 Jul 25:143:156884.
- Plants. 2026 May 14;15(10):1503.
- PeerJ. 2026 Mar 26:14:e20994.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Elder DP, et al. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci. 2016 May 25;87:88-99.

[2]. Harris JM, et al. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003 Mar;2(3):214-21.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA